89 related articles for article (PubMed ID: 17198089)
1. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring.
Schmidt J; Jäger D; Hoffmann K; Büchler MW; Märten A
J Immunother; 2007 Jan; 30(1):108-15. PubMed ID: 17198089
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Ryschich E; Märten A
J Immunother; 2008 Sep; 31(7):599-606. PubMed ID: 18600184
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
[TBL] [Abstract][Full Text] [Related]
4. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
[TBL] [Abstract][Full Text] [Related]
5. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
Knaebel HP; Märten A; Schmidt J; Hoffmann K; Seiler C; Lindel K; Schmitz-Winnenthal H; Fritz S; Herrmann T; Goldschmidt H; Krempien R; Mansmann U; Debus J; Diehl V; Büchler MW
BMC Cancer; 2005 Apr; 5():37. PubMed ID: 15826316
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.
Karakhanova S; Ryschich E; Mosl B; Harig S; Jäger D; Schmidt J; Hartwig W; Werner J; Bazhin AV
Br J Cancer; 2015 Mar; 112(6):1027-36. PubMed ID: 25742476
[TBL] [Abstract][Full Text] [Related]
7. A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2.
Märten A; Schmidt J; Ose J; Harig S; Abel U; Münter MW; Jäger D; Friess H; Mayerle J; Adler G; Seufferlein T; Gress T; Schmid R; Büchler MW
BMC Cancer; 2009 May; 9():160. PubMed ID: 19470159
[TBL] [Abstract][Full Text] [Related]
8. Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-alpha in pancreatic and periampullary cancer: results of a feasibility study.
Nitsche M; Horstmann O; Christiansen H; Hermann RM; Hess CF; Becker H; Pradier O; Schmidberger H
Cancer Radiother; 2008 Dec; 12(8):817-21. PubMed ID: 18996727
[TBL] [Abstract][Full Text] [Related]
9. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
Khallouf H; Märten A; Serba S; Teichgräber V; Büchler MW; Jäger D; Schmidt J
J Immunother; 2012 Apr; 35(3):245-53. PubMed ID: 22421942
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI).
Schmidt J; Patrut EM; Ma J; Jäger D; Knaebel HP; Büchler MW; Märten A
Cancer Immunol Immunother; 2006 Nov; 55(11):1396-405. PubMed ID: 16485127
[TBL] [Abstract][Full Text] [Related]
11. Administration of interferon-alpha in mice provokes peripheral and central modulation of immune cells, accompanied by behavioral effects.
Orsal AS; Blois SM; Bermpohl D; Schaefer M; Coquery N
Neuropsychobiology; 2008; 58(3-4):211-22. PubMed ID: 19212136
[TBL] [Abstract][Full Text] [Related]
12. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy.
Eriksen KW; Søndergaard H; Woetmann A; Krejsgaard T; Skak K; Geisler C; Wasik MA; Odum N
Mol Immunol; 2009 Feb; 46(5):812-20. PubMed ID: 18947877
[TBL] [Abstract][Full Text] [Related]
13. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer?
Pisters PW; Evans DB
Ann Surg; 2008 Aug; 248(2):152-3. PubMed ID: 18650622
[No Abstract] [Full Text] [Related]
15. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
Gigante M; Mandic M; Wesa AK; Cavalcanti E; Dambrosio M; Mancini V; Battaglia M; Gesualdo L; Storkus WJ; Ranieri E
J Immunother; 2008 Apr; 31(3):254-62. PubMed ID: 18317362
[TBL] [Abstract][Full Text] [Related]
16. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
Huguet F; André T; Hammel P; Artru P; Balosso J; Selle F; Deniaud-Alexandre E; Ruszniewski P; Touboul E; Labianca R; de Gramont A; Louvet C
J Clin Oncol; 2007 Jan; 25(3):326-31. PubMed ID: 17235048
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.
Nagano H; Miyamoto A; Wada H; Ota H; Marubashi S; Takeda Y; Dono K; Umeshita K; Sakon M; Monden M
Cancer; 2007 Dec; 110(11):2493-501. PubMed ID: 17941012
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome.
Westermann J; Hecker AC; Flörcken A; Dörken B; Pezzutto A
J Immunother; 2009; 32(6):667-75. PubMed ID: 19483643
[TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis C in the advanced adult and elderly subjects.
Gattoni A; Parlato A; Vangieri B; Bresciani M; Petraccaro M
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):145-57. PubMed ID: 19305374
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
Morak MJ; van der Gaast A; Incrocci L; van Dekken H; Hermans JJ; Jeekel J; Hop WC; Kazemier G; van Eijck CH
Ann Surg; 2008 Dec; 248(6):1031-41. PubMed ID: 19092348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]